Global Jevtana Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Jevtana Market Insights, Forecast to 2034
Jevtana is a brand name for cabazitaxel, a chemotherapy medication used in the treatment of advanced prostate cancer that has become resistant to standard hormone therapy. Jevtana works by disrupting the growth and division of cancer cells. It is administered intravenously and can be effective in cases where other treatments have failed.
Market Analysis and InsightsGlobal Jevtana Market
Global Jevtana market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Jevtana industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Jevtana key companies include Sanofi, Tapi Teva, Fuan Pharmaceutical Group and Fujian Yewpark Biological, etc. Sanofi, Tapi Teva, Fuan Pharmaceutical Group are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Jevtana were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the share will be % in 2029. Moreover, China, plays a key role in the whole Jevtana market and estimated to attract more attentions from industry insiders and investors.
Jevtana can be divided into Purity above 99% and Other Purity, etc. Purity above 99% is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2029.
Jevtana is widely used in various fields, such as Age Below 65 and Age Above 65, etc. Age Below 65 provides greatest supports to the Jevtana industry development. In 2022, global % revenue of Jevtana went into Age Below 65 filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Jevtana market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Jevtana market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report

Sanofi
Tapi Teva
Fuan Pharmaceutical Group
Fujian Yewpark Biological
Segment by Type
Purity above 99%
Other Purity
Age Below 65
Age Above 65
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Jevtana introduction, etc. Jevtana Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Jevtana
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Market Analysis and InsightsGlobal Jevtana Market
Global Jevtana market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Jevtana industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Jevtana key companies include Sanofi, Tapi Teva, Fuan Pharmaceutical Group and Fujian Yewpark Biological, etc. Sanofi, Tapi Teva, Fuan Pharmaceutical Group are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Jevtana were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the share will be % in 2029. Moreover, China, plays a key role in the whole Jevtana market and estimated to attract more attentions from industry insiders and investors.
Jevtana can be divided into Purity above 99% and Other Purity, etc. Purity above 99% is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2029.
Jevtana is widely used in various fields, such as Age Below 65 and Age Above 65, etc. Age Below 65 provides greatest supports to the Jevtana industry development. In 2022, global % revenue of Jevtana went into Age Below 65 filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Jevtana market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Jevtana market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report

By Company
Sanofi
Tapi Teva
Fuan Pharmaceutical Group
Fujian Yewpark Biological
Segment by Type
Purity above 99%
Other Purity
Segment by Application
Age Below 65
Age Above 65
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Jevtana introduction, etc. Jevtana Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Jevtana
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
